Bufei Yishen Granule for Reducing Acute Exacerbation in GOLD Stage 3 or 4 COPD

Bufei Yishen Granule for Reducing Acute Exacerbation in GOLD Stage 3 or 4 COPD: A Randomized, Double-blind, Placebo Controlled Trial

This study aims to establish the treatment scheme of Bufei Yishen granule for GOLD stage 3 or 4 chronic obstructive pulmonary disease (COPD), reducing acute exacerbation, improving exercise capacity and forming high quality evidence.

Study Overview

Detailed Description

COPD is a highly prevalent disease, with a prevalence among people 40 years of age or older of 10.1% worldwide and 13.7% in China. COPD has become the third leading cause of death worldwide. Frequent acute exacerbation and exercise limitation broadly exist in COPD patients, especially those in GOLD stage 3 or 4. Although appropriate pharmacological therapies have been proven to be effective in COPD management, however, many gaps are still to be filled. For example, the adverse effects of pharmacologic therapies can never be ignored. The investigator's previous studies suggested that traditional Chinese medicine (TCM) has effect on GOLD stage 3 or 4 COPD.

This is a multicenter, randomized, double-blind, placebo controlled trial to evaluate the effect of Bufei Yishen granule on reducing acute exacerbation in GOLD stage 3 or 4 COPD subjects. After a 14-day run-in period, 348 subjects will be randomly assigned to treatment group or control group for 52-week treatment. The primary outcomes are frequency and duration of acute exacerbation. The secondary outcomes include mortality, pulmonary function, clinical symptoms, exercise capacity, quality of life and treatment satisfaction. Safety will also be assessed.

Study Type

Interventional

Enrollment (Anticipated)

348

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Xueqing Yu, Doctor
  • Phone Number: 86-371-66248624
  • Email: yxqshi@163.com

Study Locations

    • Henan
      • Zhengzhou, Henan, China, 450000
        • The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
        • Contact:
          • Xueqing Yu, Doctor
          • Phone Number: 86-371-66248624
          • Email: yxqshi@163.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • A confirmed diagnosis of GOLD stage 3 or 4 COPD.
  • Syndrome differentiation meets criteria of Qi deficiency of the lung and spleen syndrome, Qi deficiency of the lung and kidney syndrome or Qi and Yin deficiency of the lung and kidney syndrome.
  • Age ranges from 40 years to 80 years.
  • With informed consent signed.

Exclusion Criteria:

  • Pregnant and lactating women.
  • Patients with severe cardiovascular and cerebrovascular diseases.
  • Patients with severe liver and kidney diseases.
  • Patients with asthma, bronchiectasis, active pulmonary tuberculosis, pulmonary embolism, chronic respiratory failure or other severe respiratory diseases.
  • Patients with tumor after resection, radiotherapy or chemotherapy in the past 5 years.
  • Patients with severe neuromuscular disorders, severe arthritis or severe peripheral vascular diseases.
  • Patients with severe cognitive and psychiatric disorders.
  • Patients with diabetes.
  • Patients who were administered oral glucocorticoids in the past 4 weeks.
  • Patients who have participated in other clinical studies in the past 4 weeks.
  • People who are allergic to the treatment drugs.
  • Patients who have experienced one or more acute exacerbation in the past 4 weeks.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Bufei Yishen granule plus Western medicine
Patients in this arm will receive Bufei Yishen granule in addition to Western medicine.
Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks.
Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks.
Placebo Comparator: Placebo Bufei Yishen granule plus Western medicine
Patients in this arm will receive placebo Bufei Yishen granule in addition to Western medicine.
Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks.
Placebo Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks. The placebo granule consists of dextrin, bitter and 5% of the Bufei Yishen granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency of acute exacerbation
Time Frame: Up to week 52.
Frequency of acute exacerbation will be recorded.
Up to week 52.
Duration of acute exacerbation
Time Frame: Up to week 52.
Duration of acute exacerbation will be recorded.
Up to week 52.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mortality
Time Frame: Up to week 52.
The mortality will be calculated.
Up to week 52.
FEV1
Time Frame: Change from baseline FEV1 at week 26 and 52.
Forced expiratory volume in one second ( FEV1) will be used to assess pulmonary function.
Change from baseline FEV1 at week 26 and 52.
Clinical symptom assessment questionnaire
Time Frame: Change from baseline clinical symptom assessment questionnaire scores at week 13, 26, 39 and 52.
Clinical symptom assessment questionnaire of COPD will be used to assess symptom.
Change from baseline clinical symptom assessment questionnaire scores at week 13, 26, 39 and 52.
6MWD
Time Frame: Change from baseline 6MWD at week 13, 26, 39 and 52.
Six-minute walk distance (6MWD) will be conducted to assess exercise capacity
Change from baseline 6MWD at week 13, 26, 39 and 52.
CAT
Time Frame: Change from baseline CAT scores at week 13, 26, 39 and 52.
COPD assessment test (CAT) will be used to assess quality of life.
Change from baseline CAT scores at week 13, 26, 39 and 52.
SF-36
Time Frame: Change from baseline SF-36 scores at week 13, 26, 39 and 52.
The MOS 36-Item Short-Form Health Survey (SF-36) will be used to assess quality of life.
Change from baseline SF-36 scores at week 13, 26, 39 and 52.
mCOPD-PRO
Time Frame: Change from baseline mCOPD-PRO scores at week 13, 26, 39 and 52.
The modified COPD patient-reported outcome scale (mCOPD-PRO) will be used to assess quality of life. The mCOPD-PRO contains 27 items in three domains. mCOPD-PRO scores range from 0 to 4 with a decrease in score showing higher health status.
Change from baseline mCOPD-PRO scores at week 13, 26, 39 and 52.
mESQ-COPD
Time Frame: Change from baseline mESQ-COPD scores at week 13, 26, 39 and 52.
The modified effectiveness satisfaction questionnaire for COPD (mESQ-COPD) will be used to assess treatment satisfaction. The mESQ-COPD contains 19 items in four domains. mESQ-COPD scores range from 0 to 4 with a decrease in score showing higher treatment satisfaction.
Change from baseline mESQ-COPD scores at week 13, 26, 39 and 52.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

June 1, 2019

Primary Completion (Anticipated)

June 1, 2020

Study Completion (Anticipated)

December 1, 2020

Study Registration Dates

First Submitted

May 29, 2019

First Submitted That Met QC Criteria

June 5, 2019

First Posted (Actual)

June 6, 2019

Study Record Updates

Last Update Posted (Actual)

June 6, 2019

Last Update Submitted That Met QC Criteria

June 5, 2019

Last Verified

May 1, 2019

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Obstructive Pulmonary Disease

Clinical Trials on Bufei Yishen granule

3
Subscribe